75 related articles for article (PubMed ID: 24577592)
1. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine.
Radbruch L; Lehmann K; Gockel HH; Neighbors D; Nuyts G
Eur J Health Econ; 2002 Jun; 3(2):111-9. PubMed ID: 24577592
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.
Greiner W; Lehmann K; Earnshaw S; Bug C; Sabatowski R
Eur J Health Econ; 2006 Dec; 7(4):290-6. PubMed ID: 16983521
[TBL] [Abstract][Full Text] [Related]
3. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW
Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
[TBL] [Abstract][Full Text] [Related]
5. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
6. A one year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain.
Frei A; Andersen S; Hole P; Jensen NH
J Pain Palliat Care Pharmacother; 2003; 17(2):5-26. PubMed ID: 14649386
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain.
Neighbors DM; Bell TJ; Wilson J; Dodd SL
J Pain Symptom Manage; 2001 Feb; 21(2):129-43. PubMed ID: 11226764
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach.
Hass B; Lungershausen J; Hertel N; Poulsen Nautrup B; Kotowa W; Liedgens H
Eur J Health Econ; 2009 Jul; 10(3):309-21. PubMed ID: 19101743
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of safety and efficacy of transdermal therapeutic system-fentanyl in adult patients with gynecological cancer-related pain.
Lorvidhaya V; Katanyoo K; Srisomboon J; Suprapaphorn P; Cheewakriangkrai C
J Med Assoc Thai; 2004 Mar; 87(3):319-25. PubMed ID: 15117050
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
[TBL] [Abstract][Full Text] [Related]
11. A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain.
Otis J; Rothman M
Curr Med Res Opin; 2006 Aug; 22(8):1493-501. PubMed ID: 16870074
[TBL] [Abstract][Full Text] [Related]
12. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
13. Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain.
Gallagher RM; Welz-Bosna M; Gammaitoni A
Pain Med; 2007; 8(1):71-4. PubMed ID: 17244106
[TBL] [Abstract][Full Text] [Related]
14. Calculating the cost for drug treatment including the adverse drug reactions treatment cost (primer for fentanyl TTS in Bulgaria).
Petrova GI; Getov IN
Boll Chim Farm; 2002; 141(2):150-3. PubMed ID: 12135164
[TBL] [Abstract][Full Text] [Related]
15. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers.
Mystakidou K; Parpa E; Tsilika E; Katsouda E; Kouloulias V; Kouvaris J; Georgaki S; Vlahos L
J Pain; 2004 Mar; 5(2):119-32. PubMed ID: 15042520
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of chronic pain--use of transdermal fentanyl (Durogesic TTS)].
Babić-Naglić D; Jajić Z; Gnjidić Z; Stambuk B
Reumatizam; 2002; 49(2):33-7. PubMed ID: 12476759
[TBL] [Abstract][Full Text] [Related]
17. Therapy switching in patients receiving long-acting opioids.
Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of fentanyl HCl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for postoperative pain management for patient subgroups.
Mattia C; Coluzzi F; Sonnino D; Anker-Møller E
Eur J Anaesthesiol; 2010 May; 27(5):433-40. PubMed ID: 20186064
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
Payne R
Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
[TBL] [Abstract][Full Text] [Related]
20. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
